Amgen's earnings call showcases robust financial performance, driven by strong sales growth, particularly in their inline brands and new product launches like Repatha and Kyprolis.  Management expressed confidence in the 2016 outlook, with higher revenue and EPS guidance.  Positive guidance updates, along with continued strategic focus and transformation efforts, point towards a likely positive impact on the stock price in the near term.
[1]
